Skip to content
Review Open access

The Influence of Social Determinants of Health on Treatment Delivery and Outcomes in Acute Leukemia

Nov 2026 · Current Hematologic Malignancy Reports · Vol 21 · 0 citations · 85 references
Medicine

TL;DR

Current evidence on how social determinants of health can influence multiple aspects of leukemia biology and outcomes is summarized and a framework to address the influence of SDOH along the continuum of acute leukemia care is provided.

Abstract

Acute leukemia outcomes have conventionally been predicated on the genomic characteristics of leukemia cells. However, emerging evidence from population-based and national co-operative group studies suggests a pivotal role of social determinants of health (SDOH) on acute leukemia survival outcomes. Acute leukemia outcomes over the past two decades have benefited from advances in molecular diagnostics, which have ushered in a multitude of targeted therapies including small molecule inhibitors and immunotherapies, liberalization of donor matching for transplantation, and early incorporation of supportive care. However, these advances have not benefited all populations equally. Environmental exposures, insurance status, access to transportation, and language barriers are some evaluable domains of social determinants of health (SDOH) that have been linked to leukemia outcomes. SDOH can influence leukemia outcomes through impact on patient access to specialized care, clinical trial enrollment, allogeneic stem cell transplantation, and palliative care. Beyond well-established disparities in access to care, emerging epidemiologic evidence suggests that SDOH may influence the genomic and biological characteristics of leukemia. Clinical prognostic leukemia models such as ELN 2022 do not accurately predict chemotherapy outcomes in diverse patient populations. This may be attributable to biologic differences in leukemia conferred by the social and heritable aspects of race. With the current landscape shifting to incorporate small-molecule inhibitors and immunotherapies into the frontline treatment of leukemia, SDOH-informed risk stratification can optimize prognostication and guide vulnerable patients toward less toxic, equally effective therapeutic alternatives. This review summarizes current evidence on how social determinants of health can influence multiple aspects of leukemia biology and outcomes and provides a framework to address the influence of SDOH along the continuum of acute leukemia care.

Read PDF

Similar papers

Review Open access Mar 2025

CANCER AND SOCIAL DETERMINANTS OF HEALTH: EXAMINING THE IMPACT OF ECONOMIC, GEOGRAPHIC, AND RACIAL DISPARITIES IN TREATMENT OUTCOMES: A REVIEW

Cancer is a leading global health concern, responsible for significant morbidity and mortality. However, treatment outcomes are not solely determined by biological factors but are heavily influenced by social determinants of health (SDOH), including economic status, geographic location, and racial and ethnic background...

Mary Oyeleke, M. Owusu, Rasheed Yusuf · 0 citations
Open access Sep 2026

Child Opportunity Index and Survival After Pediatric Hematopoietic Cell Transplantation for Acute Leukemia

In this single-institution cohort, children from very low opportunity neighborhoods experienced inferior survival after HCT for acute leukemia in exploratory analyses, and neighborhood opportunity should be investigated in larger, multi-institutional cohorts as a clinical risk factor for poor outcomes.

Katherine T. Lind, Cheng-Chang Wu, A. Nicklawsky et al. · 0 citations
Open access Oct 2026

Cumulative impact of social determinants of health on outcomes after immunotherapy for lung cancer: A real-world analysis.

234 Background: Social determinants of health (SDOH) can have deleterious impact on lung cancer outcomes. Individually, SDOH increase progression risk, but their cumulative impact has not been well studied. We examined the combined and cumulative impact of SDOH on lung cancer progression and mortality. Methods...

Amir Mehdizadeh-Shrifi, F. Lennartz, Tabea Fröhlich et al. · 0 citations
Review Open access Sep 2026

Healthcare utilization patterns and systemic barriers to care among adult hematologic malignancy survivors

Advances in treatment for hematologic malignancies have created a rapidly growing population of long-term survivors who carry a substantial and compounding burden of treatment-related late effects. As survival rates improve across leukemias, lymphomas, and multiple myeloma, the healthcare system faces increasing pressu...

Shefali Pati, Indushekar Manjunatha, T. Allen et al. · 0 citations
Oct 2026

Abstract C149: Assessing the impact of the Affordable Care Act on reducing racial disparities in insurance rates and mortality for childhood Acute Lymphoblastic Leukemia survivors: A report from the Children's Oncology Group

Childhood cancer remains one of the leading causes of death from disease among children Despite novel therapeutic options and improved risk stratification over the past several decades, substantial racial and ethnic disparities in outcome persist. The Patient Protection and Affordable Care Act (ACA) sought to imp...

Jinhee Cha, Helen M. Parsons, Logan G. Spector et al. · 0 citations
Open access Sep 2026

Are there inequalities in colon cancer diagnosis and treatment in England? A population-based study.

INTRODUCTION Socioeconomic inequalities in cancer outcomes persist across many high-income countries, including those with universal healthcare systems. Evidence suggests that patients from more deprived populations may experience differences in access to cancer treatment and diagnostic pathways. This study examined so...

B. Pickwell-Smith, L. Paton, I. Soyiri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.